Seroprevalence of IgG against conformational and linear capsid antigens of parvovirus B19 in Italian blood donors

Serum samples from 446 Italian blood donors between 18 and 65 years of age were analysed for the presence of IgG against parvovirus B19 capsid proteins VP1 and VP2 including conformational and linear epitopes. The overall prevalence of IgG against parvovirus B19 capsid proteins VP1 and VP2 against at least one antigen type was 79·1%. No significant difference was found between men and women. In the 18–27 years age group, 77·0% of the population had experienced infection with the virus, reaching 88·5% in the 48–57 years age group. The overall prevalence of IgG was 78·0% against conformational VP1+VP2 antigens, 74·9% against conformational VP2, 70·9% against linear VP1 and 23·3% against linear VP2 in the analysis of the IgG response against different conformational and linear epitopes of VP1 and VP2. Although IgG against conformational VP1+VP2, conformational VP2 and linear VP1 was present in more than 60% of subjects in all age groups, IgG against VP2 linear antigens was present in only 32% of subjects in the 18–27 years age group and then decreased to 20·5% in the 28–37 years age group. A different trend was noted when IgG positivity against linear and conformational epitopes was analysed separately in men and women. A significant increase was found in seroprevalence of IgG against VP2 conformational antigens with increasing age in males and a significant decrease in seroprevalence of IgG against VP2 linear antigens in women with increasing age.

[1]  K. Brown,et al.  Human Parvovirus B19 , 2002, Clinical Microbiology Reviews.

[2]  P. Vial,et al.  Seroprevalence of parvovirus B19 in urban Chilean children and young adults, 1990 and 1996 , 2002, Epidemiology and Infection.

[3]  J. Kerr Pathogenesis of human parvovirus B19 in rheumatic disease , 2000, Annals of the rheumatic diseases.

[4]  H. Kelly,et al.  The age-specific prevalence of human parvovirus immunity in Victoria, Australia compared with other parts of the world , 2000, Epidemiology and Infection.

[5]  A. Theamboonlers,et al.  Prevalence of antibodies to parvovirus B 19 in Thailand. , 2000, The Southeast Asian journal of tropical medicine and public health.

[6]  P. Andersen,et al.  Risk factors for parvovirus B19 infection in pregnancy. , 1999, JAMA.

[7]  M. Zerbini,et al.  IgG immune response to B19 parvovirus VP1 and VP2 linear epitopes by immunoblot assay , 1999, Journal of medical virology.

[8]  Chien-Jen Chen,et al.  Seroepidemiology of human parvovirus B19 in Taiwan , 1999, Journal of medical virology.

[9]  S. Doyle,et al.  Undenatured parvovirus B19 antigens are essential for the accurate detection of parvovirus B19 IgG , 1999, Journal of medical virology.

[10]  H. M. van den Berg,et al.  High Prevalence of Parvovirus B19 IgG Antibodies among Dutch Hemophilia Patients , 1998, Vox Sanguinis.

[11]  G. Vanham,et al.  Higher prevalence of parvovirus B19 in Belgian as compared to Tunisian blood donors: differential implications for prevention of transfusional transmission. , 1997, Transfusion science.

[12]  W. Lim,et al.  Parvovirus B19 infection in Hong Kong. , 1997, The Journal of infection.

[13]  A. Athanasiadis,et al.  Human parvovirus B19: immunity of Greek females and prenatal investigation of hydrops fetalis. , 1997, European journal of obstetrics, gynecology, and reproductive biology.

[14]  S. Kajigaya,et al.  Immune Response to B19 Infection , 1997 .

[15]  A. Pacsa,et al.  Seroprevalence of human parvovirus B19 in children of a desert region. , 1996, Annals of tropical paediatrics.

[16]  Yasuko Matsunaga,et al.  組換え (VP1+VP2) 粒子抗原を用いたヒトパルボウイルスB19の血清疫学 , 1995 .

[17]  K. Hedman,et al.  Epitope type-specific IgG responses to capsid proteins VP1 and VP2 of human parvovirus B19. , 1995, The Journal of infectious diseases.

[18]  N. Takeda,et al.  [Seroepidemiology of human parvovirus B19 using recombinant VP1 + VP2 particle antigen]. , 1995, Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases.

[19]  K. Goh,et al.  Low prevalence of antibody to human parvovirus B19 in Singapore , 1994, Epidemiology and Infection.

[20]  M. J. Norušis,et al.  SPSS/PC+ base system user's guide, version 5.0 , 1992 .

[21]  U. Desselberger,et al.  Prevalence of human parvovirus (B19) and rubellavirus infections in urban and remote rural areas in northern Brazil , 1990, Journal of medical virology.

[22]  K. Brown,et al.  The prevalence of antibody to human parvovirus B19 in Rio de Janeiro, Brazil. , 1990, Revista do Instituto de Medicina Tropical de Sao Paulo.

[23]  S. Adler,et al.  Human parvovirus B19 infections in women of childbearing age and within families. , 1989, The Pediatric infectious disease journal.

[24]  B. Cohen,et al.  The prevalence of antibody to human parvovirus B19 in England and Wales. , 1988, Journal of medical microbiology.

[25]  M. Söderlund-Venermo,et al.  [Human parvoviruses]. , 1987, Annales de pediatrie.